About FDA

Office of Unapproved Drugs and Labeling Compliance (OUDLC)

OUDLC’s Mission

To promote and protect public health through science driven, comprehensive, strategies and actions that communicate potential risks about drug products and minimize exposure to unsafe, ineffective, or poor quality unapproved or misbranded drugs.  

OUDLC’s Vision

Using scientific, risk based strategies, and comprehensive compliance, we are global leaders in the effort to eliminate exposure to unapproved or misbranded drugs.   

Immediate Office

Office Director: Steve Tave (acting)

Deputy Office Director: Kathleen Anderson, Pharm.D.

Associate Director for Policy and Communication: Gail Bormel, J.D., R.Ph. (acting)

Associate Director for Program Management and Organizational Strategy: Alisea Crowley (acting)

Associate Director for Risk Science, Intelligence, and Prioritization: Meghan Murphy, Ph.D.

Senior Medical Advisor: Arthur Simone, (detail)

Director, Division of Prescription Drugs: Gail Bormel, J.D., R.Ph. (acting)

Director, Division of Non-Prescription Drugs and Health Fraud: Elizabeth Miller, Pharm.D.  


Mailing Address

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Compliance
Office of Unapproved Drugs and Labeling Compliance
10903 New Hampshire Ave.
Silver Spring, MD 20993
Ph:  (301) 796-3110
Fax: (301) 847-8745
Email: OUDLCMail@fda.hhs.gov





Page Last Updated: 09/22/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English